Lynn S. Ashby

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Tracy T. Batchelor, Paul Mulholland, Bart Neyns et al. · Journal of Clinical Oncology · 2013 · 585 citations · Full text

An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity

Mark E. Oppenlander, Andrew B. Wolf, Laura A. Snyder et al. · Journal of neurosurgery · 2014 · 262 citations

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539

Leland Rogers, Peixin Zhang, Michael A. Vogelbaum et al. · Journal of neurosurgery · 2017 · 259 citations · Full text

Intermediate-risk Meningioma, Surgical Oncology, Cancer Management +17

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Burt Nabors, Karen Fink, Tom Mikkelsen et al. · Neuro-Oncology · 2015 · 231 citations · Full text